文拉法辛缓释片治疗抑郁症临床对照观察  

Clinic contrast study of Venlafaxine slow release tablets for treatment of depression

作　　者：徐海春[1] 王雪宏[1] 高林[1] 

机构地区：[1]沈阳市于洪区红十字会医院心理科,辽宁沈阳110033

出　　处：《中国民康医学》2010年第10期1217-1217,1334,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:评价文拉法辛缓释片治疗抑郁症的疗效与安全性。方法:将76例抑郁症患者随机分为文拉法辛缓释片组38例、氟西汀组38例,疗程8周。以汉密尔顿抑郁量表(HAMD)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:两组治疗2周后HAMD评分比较差异有统计学意义(P<0.05)。两组疗效及治疗后4周、8周HAMD评分比较,均无明显差异(P>0.05);各组治疗后与治疗前的HAMD评分比较差异均有统计学意义(P<0.05),不良反应发生率无明显差异(P>0.05)。结论:文拉法辛缓释片治疗抑郁症疗效确切,起效快,安全性好。Objective： To evaluate the efficacy and safety of depression treated by venlafaxine - xr. Methods： Seventy six cases with depression were divided randomly into Venlafaxine group（38 cases） and Fluoxetine group（38 cases）. Hamilton depression rating scale（HAMD） and treatment emergent symptom scale（TESS） were used.Results： The HAMD scores lowered more significantly since the end of the 2nd week in the research treatment（ P 〈 0.05） and there were no significant differences at other time-points（ P 〉 0.05）. Both groups compared with pretreatment lowered more significantly（ P 〈 0.05）. There were no significant difference between two groups in side effects（ P 〉 0. 05 ）. Conclusion： Depression treated with Venlafaxine- xr had definite efficacy, rapid onset and good safety.

关 键 词：文拉法辛 缓释片 氟西汀 抑郁症 

分 类 号：R749.4[医药卫生—神经病学与精神病学]